偶发影像学发现的患病率与结局:伞状综述
该伞状综述检索MEDLINE和EMBASE至2017年8月,纳入20篇系统综述(240项原始研究),评估偶发影像学发现(偶发瘤)的患病率与结局。偶发瘤患病率在影像检查间差异大:胸部CT偶发肺栓塞及全身PET或PET/CT低于5%,心脏MRI、胸部CT(胸部、腹部、脊柱或心脏偶发瘤)及CT结肠镜(结肠外偶发瘤)超过三分之一,脊柱MRI和脑MRI为22%。偶发瘤恶性率因器官而异:脑、腮腺和肾上腺低于5%,结肠外、前列腺和结肠为10%至20%,肾、甲状腺和卵巢约四分之一,乳腺最高为42%(95%CI 31%至54%)。20项Meta分析中15项异质性I²>50%。作者认为该结果有助于临床医生和患者权衡影像检查利弊及偶发瘤诊断后的管理决策,并可为制定指南提供依据。
要点
- 偶发瘤患病率因影像检查而异:胸部CT偶发肺栓塞及全身PET或PET/CT低于5%,心脏MRI、胸部CT(胸部、腹部、脊柱或心脏偶发瘤)及CT结肠镜(结肠外偶发瘤)超过三分之一。
- 脊柱MRI和脑MRI的偶发瘤患病率为22%。
- 偶发瘤恶性率因器官而异:脑、腮腺和肾上腺低于5%;结肠外、前列腺和结肠为10%至20%;肾、甲状腺和卵巢约四分之一;乳腺最高为42%(95%CI 31%至54%)。
- 20项Meta分析中15项异质性I²>50%,提示研究间异质性高。
- 作者认为该伞状综述有助于临床医生和患者权衡影像检查利弊及偶发瘤诊断后的管理决策,并可为制定指南提供依据。
适用人群与场景
- 健康无症状患者或症状不 apparent 与影像异常无关的症状性患者中的偶发影像学发现(偶发瘤)。
- 敏感性分析中亦考虑测量有恶性肿瘤病史患者偶发瘤患病率的原始研究。
诊断标准与关键阈值
- 偶发影像学发现定义为健康无症状患者的影像异常,或症状性患者的影像异常 but 该异常与患者症状无明显关联。
- 纳入标准为提供偶发异常(偶发瘤)患病率的观察性研究的系统综述和Meta分析。
研究设计与关键结果
- 伞状综述纳入20篇系统综述(240项原始研究),来自数据库检索7098篇参考文献。
- 15篇系统综述提供偶发瘤患病率数据,18篇提供偶发瘤结局数据(13篇两者均提供)。
- 偶发瘤患病率低于5%见于:癌症患者和非癌症患者的胸部CT偶发肺栓塞,以及癌症患者和非癌症患者的全身PET或PET/CT。
- 偶发瘤患病率超过三分之一见于:心脏MRI、胸部CT(胸部、腹部、脊柱或心脏偶发瘤)及CT结肠镜(结肠外偶发瘤)。
- 脊柱MRI偶发瘤患病率为22%,脑MRI为22%。
- 偶发瘤恶性率低于5%见于脑、腮腺和肾上腺偶发瘤。
- 结肠外、前列腺和结肠偶发瘤恶性率为10%至20%。
- 肾、甲状腺和卵巢偶发瘤恶性率约为四分之一。
证据类型、等级与局限
- 证据类型:系统综述的伞状综述。
- 局限:20项Meta分析中15项异质性I²>50%(原文报告高异质性)。
对床旁实践的改变
- 作者认为该伞状综述有助于临床医生和患者权衡影像检查的利弊,并有助于偶发瘤诊断后的管理决策。
- 作者认为该结果可为制定辅助这些决策的指南提供依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To provide an overview of the evidence on prevalence and outcomes of incidental imaging findings.
DESIGN: Umbrella review of systematic reviews.
DATA SOURCES: Searches of MEDLINE, EMBASE up to August 2017; screening of references in included papers.
ELIGIBILITY CRITERIA: Criteria included systematic reviews and meta-analyses of observational studies that gave a prevalence of incidental abnormalities ("incidentalomas"). An incidental imaging finding was defined as an imaging abnormality in a healthy, asymptomatic patient or an imaging abnormality in a symptomatic patient, where the abnormality was not apparently related to the patient's symptoms. Primary studies that measured the prevalence of incidentalomas in patients with a history of malignancy were also considered in sensitivity analyses.
RESULTS: 20 systematic reviews (240 primary studies) were identified from 7098 references from the database search. Fifteen systematic reviews provided data to quantify the prevalence of incidentalomas, whereas 18 provided data to quantify the outcomes of incidentalomas (13 provided both). The prevalence of incidentalomas varied substantially between imaging tests; it was less than 5% for chest computed tomography for incidental pulmonary embolism in patients with and without cancer and whole body positron emission tomography (PET) or PET/computed tomography (for patients with and without cancer). Conversely, incidentalomas occurred in more than a third of images in cardiac magnetic resonance imaging (MRI), chest computed tomography (for incidentalomas of thorax, abdomen, spine, or heart), and computed tomography colonoscopy (for extra-colonic incidentalomas). Intermediate rates occurred with MRI of the spine (22%) and brain (22%). The rate of malignancy in incidentalomas varied substantially between organs; the prevalence of malignancy was less than 5% in incidentalomas of the brain, parotid, and adrenal gland. Extra-colonic, prostatic, and colonic incidentalomas were malignant between 10% and 20% of the time, whereas renal, thyroid, and ovarian incidentalomas were malignant around a quarter of the time. Breast incidentalomas had the highest percentage of malignancy (42%, 95% confidence interval 31% to 54%). Many assessments had high between-study heterogeneity (15 of 20 meta-analyses with I2 >50%).
CONCLUSIONS: There is large variability across different imaging techniques both in the prevalence of incidentalomas and in the prevalence of malignancy for specific organs. This umbrella review will aid clinicians and patients weigh up the pros and cons of requesting imaging scans and will help with management decisions after an incidentaloma diagnosis. Our results can underpin the creation of guidelines to assist these decisions.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD42017075679.
参考来源
- O'Sullivan JW, Muntinga T, Grigg S, et al. Prevalence and outcomes of incidental imaging findings: umbrella review. BMJ. 2018. PMID: 29914908. doi:10.1136/bmj.k2387
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。